Comparative Pharmacology
Head-to-head clinical analysis: PLACIDYL versus SONATA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PLACIDYL versus SONATA.
PLACIDYL vs SONATA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ethchlorvynol is a sedative-hypnotic that depresses the central nervous system at the level of the brainstem and reticular formation, potentiating GABAergic inhibition. Its exact molecular mechanism is not fully defined.
Zaleplon is a non-benzodiazepine hypnotic that selectively binds to the benzodiazepine type 1 (BZ1) receptor subtype on the gamma-aminobutyric acid (GABA) A receptor complex, potentiating GABA-mediated chloride ion influx and neuronal inhibition.
500 mg to 1000 mg orally at bedtime, as a hypnotic. Usual dose is 500 mg to 750 mg. Maximum dose 1000 mg.
10 mg orally at bedtime; range 5-20 mg; maximum 20 mg per day.
None Documented
None Documented
Terminal elimination half-life is approximately 24 hours (range 10-40 hours), with prolonged elimination in hepatic impairment and overdose due to saturation of metabolism.
Terminal elimination half-life is approximately 1 hour (range 0.7–1.7 h) in healthy adults; elderly patients and those with hepatic impairment may have prolonged half-life (up to 2–3 h).
Primarily renal excretion of metabolites; less than 1% excreted unchanged. Biliary/fecal elimination accounts for 30-40% of metabolites, with enterohepatic recycling.
Approximately 83% of administered radioactivity is excreted in urine (with less than 1% as unchanged drug) and 17% in feces.
Category C
Category C
Sedative-Hypnotic
Sedative-Hypnotic